Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

One of the highlights of Eli Lilly's ... up by the drugmaker. Lilly's head of diabetes, Mike Mason, said on the company's results call that the rollout of Mounjaro (tirzepatide) was "really ...

That’s how much Eli Lilly’s revenue grew in 2024 ... the revision to lower-than-expected sales of tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...